Technical Analysis for FIXX - Homology Medicines, Inc.

Grade Last Price % Change Price Change
F 7.03 -2.63% -0.19
FIXX closed down 2.63 percent on Thursday, April 15, 2021, on 1.12 times normal volume. Due to the stock's strong downtrend, it may remain oversold for a while. So, if you're looking for a reason to buy, don't put too much weight on it being oversold.
Earnings due: May 5
*** please verify all earnings dates ***

Trend Table & Recent EOD Signals

ADX Long Term Intermediate Term Short Term
Strong Down Down Down
Historical FIXX trend table...

Date Alert Name Type % Chg
New 52 Week Closing Low Bearish 0.00%
Wide Bands Range Expansion 0.00%
Oversold Stochastic Weakness 0.00%
180 Bearish Setup Bearish Swing Setup -2.63%
Slingshot Bearish Bearish Swing Setup -2.63%
Calm After Storm Range Contraction -2.63%
Wide Bands Range Expansion -2.63%
Oversold Stochastic Weakness -2.63%
Hammer Candlestick Bullish -2.09%
Lizard Bullish Bullish Day Trade Setup -2.09%
Older End-of-Day Signals for FIXX ...

   Recent Intraday Alerts -- Get these alerts pushed to you via our Mobile App

Alert Time
Down 2 % about 8 hours ago
Down 1% about 9 hours ago
Bearish 180 Entry about 9 hours ago
Slingshot Bearish Entry about 9 hours ago
Fell Below Previous Day's Low about 9 hours ago
View Earlier Intraday Alerts

Free Daily (Stock) Chart Reading

Let us help you stay on top of your investments. We will alert you to important technical developments on your portfolio & watchlist.

Profile

Homology Medicines, Inc. Description

Homology Medicines, Inc., a genetic medicines company, focuses on transforming the lives of patients suffering from rare genetic diseases. Its proprietary platform is designed to utilize its human hematopoietic stem cell derived adeno-associated virus vectors (AAVHSCs) to deliver genetic medicines in vivo either through a gene therapy or nuclease-free gene editing across a range of genetic disorders. The company's various set of AAVHSCs allows company to target, through a single injection, a range of disease-relevant tissues, including the liver, central nervous system, peripheral nervous system, bone marrow, muscle, and eye. Its lead product candidate is HMI-102, which is in Phase 1/2 pheNIX clinical trial, a gene therapy for the treatment of phenylketonuria (PKU) in adults. The company also develops HMI-103 for the treatment of PKU in pediatric patients; and HMI-202 to treat metachromatic leukodystrophy. Homology Medicines, Inc. was founded in 2015 and is based in Bedford, Massachusetts.


Classification

Sector: Healthcare
Industry: Biotechnology
Keywords: Medicine Biology Eye Bone Rare Diseases Molecular Biology Gene Therapy Medical Genetics Genetic Disease Dystrophy Genetic Diseases Applied Genetics Bone Marrow Hematopoietic Stem Cell Gene Delivery Genetic Disorder Genetic Disorders Rare Genetic Disease Rare Genetic Diseases Phenylketonuria Pku Peripheral Nervous System Leukodystrophy

Is FIXX a Buy, Sell or Hold?

Indicator Bull Case Neutral / Hold Bear Case
50 DMA
200 DMA
ADX Trend
Oversold / Overbought
Relative Strength

Indicators

Indicator Value
52 Week High 17.34
52 Week Low 6.76
Average Volume 618,960
200-Day Moving Average 11.46
50-Day Moving Average 10.54
20-Day Moving Average 8.85
10-Day Moving Average 7.91
Average True Range 0.55
ADX 37.72
+DI 14.58
-DI 43.71
Chandelier Exit (Long, 3 ATRs ) 9.48
Chandelier Exit (Short, 3 ATRs ) 8.42
Upper Bollinger Band 11.37
Lower Bollinger Band 6.33
Percent B (%b) 0.14
BandWidth 56.94
MACD Line -0.95
MACD Signal Line -0.81
MACD Histogram -0.1475
Fundamentals Value
Market Cap 318.21 Million
Num Shares 45.3 Million
EPS -2.18
Price-to-Earnings (P/E) Ratio -3.23
Price-to-Sales 191.93
Price-to-Book 2.60
Pivot Point Level Traditional / Classic Fibonacci Demark Woodie Camarilla
Resistance 4 (R4) 7.66
Resistance 3 (R3) 7.72 7.56 7.56
Resistance 2 (R2) 7.56 7.40 7.54 7.52
Resistance 1 (R1) 7.30 7.30 7.22 7.24 7.48
Pivot Point 7.14 7.14 7.11 7.12 7.14
Support 1 (S1) 6.88 6.98 6.80 6.82 6.58
Support 2 (S2) 6.72 6.88 6.70 6.54
Support 3 (S3) 6.46 6.72 6.51
Support 4 (S4) 6.40